NCT01755871View on ClinicalTrials.gov

Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis

PHASE4TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Fingolimod

0,5mg Fingolimod once a day

Trial Locations (1)

40225

Heinrich Heine Universität Düsseldorf, Düsseldorf

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Heinrich-Heine University, Duesseldorf

OTHER